{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:53Z","timestamp":1761894773639},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.3816\/clm.2006.n.048","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:11:10Z","timestamp":1221095470000},"page":"115-124","source":"Crossref","is-referenced-by-count":6,"title":["Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability"],"prefix":"10.3816","volume":"7","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.048_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2006.n.048_bib2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib3","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1200\/JCO.2005.03.911","article-title":"Improved survival for patients with follicular lymphoma","volume":"23","author":"Lister","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib4","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP study","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2141.2002.03256.x","article-title":"A sequence of immunochemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma","volume":"116","author":"Lazzarino","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.048_bib7","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic haematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"Van Besien","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11864-005-0034-x","article-title":"Follicular lymphoma: management options in the era of targeted therapy","volume":"6","author":"Peterson","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib9","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: current status and future perspectives","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib10","first-page":"104","article-title":"Current status and perspective of antibody therapy in follicular lymphoma","volume":"91","author":"Buske","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.n.048_bib11","first-page":"39","article-title":"Treatment of follicular non-Hodgkin's lymphoma","volume":"4","author":"Maloney","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.3816\/CLM.2006.n.048_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02841860151116286","article-title":"A systemic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma","volume":"40","author":"Brandt","year":"2001","journal-title":"Acta Oncologica"},{"key":"10.3816\/CLM.2006.n.048_bib13","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib14","first-page":"S58","article-title":"Ifosfamide combinations in lymphoma","volume":"17","author":"Cabanillas","year":"1990","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.21219","article-title":"Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"104","author":"Oki","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/10428190500178779","article-title":"Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma","volume":"46","author":"Alinari","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.048_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.coc.0000144812.74663.d0","article-title":"A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study","volume":"28","author":"Ganjoo","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.coc.0000143015.66143.22","article-title":"A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma","volume":"28","author":"Larson","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1987.5.4.556","article-title":"MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease","volume":"5","author":"Hagemeister","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/asheducation-2000.1.166","article-title":"Managing indolent lymphomas in relapse: working our way through a plethora of options","volume":"1","author":"Cabanillas","year":"2000","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.3816\/CLM.2006.n.048_bib21","first-page":"816","article-title":"Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed\/refractory lymphoma patients","volume":"87","author":"Zinzani","year":"2002","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.n.048_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP -an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0609.1996.tb01384.x","article-title":"Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy","volume":"57","author":"Niitsu","year":"1996","journal-title":"Eur J Haematol"},{"issue":"suppl 64","key":"10.3816\/CLM.2006.n.048_bib25","first-page":"41","article-title":"DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)","volume":"66","author":"Coleman","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.n.048_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1634\/theoncologist.10-2-150","article-title":"The role of mitoxantrone in the treatment of indolent lymphomas","volume":"10","author":"Hagemeister","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2006.n.048_bib27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1389201013378581","article-title":"Non-Hodgkin's lymphoma: review of conventional treatments","volume":"2","author":"Multani","year":"2001","journal-title":"Curr Pharm Biotechnol"},{"key":"10.3816\/CLM.2006.n.048_bib29","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1053\/sonc.2002.33531","article-title":"Challenges in treating hematologic malignancies","volume":"29","author":"Voliotis","year":"2002","journal-title":"Semin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2006.n.048_bib30","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.critrevonc.2003.04.002","article-title":"Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas","volume":"48","author":"Zinzani","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.3816\/CLM.2006.n.048_bib31","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1053\/sonc.2002.33534","article-title":"Age, anemia, and fatigue","volume":"29","author":"Aapro","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/107327489900600504","article-title":"Pharmacology of chemotherapy in the older cancer patient","volume":"6","author":"Balducci","year":"1999","journal-title":"Cancer Control"},{"key":"10.3816\/CLM.2006.n.048_bib33","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/sonc.2002.33532","article-title":"The effects of anemia in hematologic malignancies: more than a symptom","volume":"29","author":"Littlewood","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib34","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/sonc.2002.33533","article-title":"Anemia of hematologic malignancies: what are the treatment options?","volume":"29","author":"Ludwig","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib35","first-page":"S2","article-title":"The impact and management of anaemia in haematological malignancies","volume":"17","author":"Coiffier","year":"2000","journal-title":"Med Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cncr.11861","article-title":"Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma","volume":"100","author":"Balducci","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/107327480301000607","article-title":"Evidence-based use of colonystimulating factors in elderly cancer patients","volume":"10","author":"Lyman","year":"2003","journal-title":"Cancer Control"},{"key":"10.3816\/CLM.2006.n.048_bib38","first-page":"S66","article-title":"The experience of chemotherapy-induced neutropenia: quality-of-life interviews with adult cancer patients","volume":"2","author":"Ashley","year":"2004","journal-title":"J Support Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emtogenicity of cancer chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2005.12.001","article-title":"Gastrointestinal toxicity of chemotherapeutic agents","volume":"33","author":"Mitchell","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous toxicities of cancer therapy","volume":"14","author":"Alley","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.048_bib43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer. Clinical signs and optimal management","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"key":"10.3816\/CLM.2006.n.048_bib44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/1097-0142(19940301)73:5<1509::AID-CNCR2820730531>3.0.CO;2-G","article-title":"Hallucinations and ifosfamideinduced neurotoxicity","volume":"73","author":"DiMaggio","year":"1994","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(19880701)62:1<32::AID-CNCR2820620108>3.0.CO;2-X","article-title":"Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma","volume":"62","author":"Leff","year":"1988","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib46","first-page":"77","article-title":"Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation","volume":"13","author":"Imrie","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2006.n.048_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10428190310001595704","article-title":"High dose chlorambucil in the treatment of lymphoid malignancies","volume":"45","author":"Nicolle","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.048_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminoncol.2005.11.011","article-title":"Renal toxicities of chemotherapy","volume":"33","author":"de Jonge","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.seminoncol.2005.11.006","article-title":"Vascular toxicity of antineoplastic agents","volume":"33","author":"Shahab","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib50","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone","year":"1999","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.n.048_bib51","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood.V87.7.2649.bloodjournal8772649","article-title":"Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors","volume":"87","author":"Aplan","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdf109","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute leukaemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"13","author":"Hosing","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3322\/canjclin.53.3.172","article-title":"Ongoing care of patients after primary treatment for their cancer","volume":"53","author":"Kattlove","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLM.2006.n.048_bib54","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","article-title":"Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia","volume":"82","author":"Brennan","year":"2000","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib55","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin's lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2006.n.048_bib56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2006.n.048_bib57","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1634\/theoncologist.8-suppl_2-17","article-title":"Cardiac safety of liposomal anthracyclines","volume":"8","author":"Safra","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2006.n.048_bib58","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O","article-title":"Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps","volume":"15","author":"Siegel","year":"1990","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.1987.5.6.927","article-title":"Cerebellar toxicity with high-dose cytosine arabinoside","volume":"5","author":"Herzig","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib61","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.3816\/CLM.2006.n.048_bib62","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.20.2.485","article-title":"Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer","volume":"20","author":"Ahles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.1998.00960.x","article-title":"Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies","volume":"103","author":"Ketterer","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.048_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.n.048_bib65","first-page":"424s","article-title":"The impact of Initials treatment of advanced stage indolent lymphoma on the risk of transformation","volume":"24","author":"Al-Tourah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib66","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(05)62951-0","article-title":"Carmustine and the lungs","volume":"349","author":"Schmitz","year":"1997","journal-title":"Lancet"},{"key":"10.3816\/CLM.2006.n.048_bib67","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/bjc.1997.178","article-title":"Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease","volume":"75","author":"Rubio","year":"1997","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2006.n.048_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminoncol.2005.11.005","article-title":"Pulmonary toxicity of chemotherapy","volume":"33","author":"Meadors","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3322\/canjclin.54.4.208","article-title":"Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors","volume":"54","author":"Oeffinger","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLM.2006.n.048_bib70","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/0140-6736(93)90523-J","article-title":"Ifosfamide and exacerbation of cisplatin-induced hearing loss","volume":"341","author":"Meyer","year":"1993","journal-title":"Lancet"},{"key":"10.3816\/CLM.2006.n.048_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0009-9260(97)80253-X","article-title":"Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids","volume":"52","author":"Thornton","year":"1997","journal-title":"Clin Radiol"},{"key":"10.3816\/CLM.2006.n.048_bib72","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1159\/000067835","article-title":"Impact of cancer therapy on the reproductive axis","volume":"59","author":"M\u00fcller","year":"2003","journal-title":"Horm Res"},{"key":"10.3816\/CLM.2006.n.048_bib73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jncimonographs\/lgi015","article-title":"Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a","volume":"34","author":"Blumenfeld","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.3816\/CLM.2006.n.048_bib74","doi-asserted-by":"crossref","first-page":"107a","DOI":"10.1182\/blood.V106.11.353.353","article-title":"Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera\u00ae) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized Intergroup clinical trial","volume":"106","author":"van Oers","year":"2005","journal-title":"Blood"},{"issue":"16 suppl","key":"10.3816\/CLM.2006.n.048_bib75","first-page":"567s","article-title":"Combined immunochemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma \u2014 follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Dreyling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib76","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib77","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade follicular, or transformed, B-cell non-Hodgkin's lymphomas","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib78","first-page":"2453","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low grade or transformed low-grade B-cell non-Hodgkin's lymphoma","volume":"20","author":"Kaminski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/104281904000025104","article-title":"Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma","volume":"46","author":"Dermime","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.048_bib80","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib81","first-page":"51","article-title":"Rituximab plus mitoxantrone, chlorambucil, prednisolone (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma \u2014 results of a phase III study (OSHO39)","volume":"16","author":"Herold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib82","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib83","doi-asserted-by":"crossref","first-page":"49a","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to \u03b1IFNCHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomised trial in 359 patients","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10428199609052435","article-title":"Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival","volume":"20","author":"Aviles","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.048_bib85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib86","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","article-title":"Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization","volume":"16","author":"Arranz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib87","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809","volume":"18","author":"Fisher","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib88","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib89","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"issue":"16 suppl","key":"10.3816\/CLM.2006.n.048_bib90","first-page":"566s","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib91","doi-asserted-by":"crossref","first-page":"262a","DOI":"10.1182\/blood.V104.11.914.914","article-title":"High dose therapy\/ASCT with rituximab for in vivo purging and post-ASCT consolidation in relapsed follicular lymphoma achieves prolonged clinical and molecular remissions","volume":"104","author":"Woods","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib92","doi-asserted-by":"crossref","first-page":"214a","DOI":"10.1182\/blood.V104.11.214.214","volume":"104","author":"Morschhauser","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.048_bib93","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.048_bib94","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1200\/JCO.2005.03.343","article-title":"Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy","volume":"23","author":"Ahles","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:10:19Z","timestamp":1588918219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1557919011703134"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.048","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}